guest ::
| Home > Publications Database > Evidence for reduced synaptic protein SNAP-25 in cerebrospinal fluid in major depressive disorder and schizophrenia. > print |
| Home > Publications Database > Evidence for reduced synaptic protein SNAP-25 in cerebrospinal fluid in major depressive disorder and schizophrenia. > print |
| 001 | 280790 | ||
| 005 | 20250907001914.0 | ||
| 024 | 7 | _ | |a 10.1136/bmjment-2025-301752 |2 doi |
| 024 | 7 | _ | |a pmid:40840974 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC12374683 |2 pmc |
| 024 | 7 | _ | |a 1362-0347 |2 ISSN |
| 024 | 7 | _ | |a 1468-960X |2 ISSN |
| 024 | 7 | _ | |a 2755-9734 |2 ISSN |
| 024 | 7 | _ | |a altmetric:180859246 |2 altmetric |
| 037 | _ | _ | |a DZNE-2025-00974 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Steinacker, Petra |0 0000-0001-6697-6522 |b 0 |
| 245 | _ | _ | |a Evidence for reduced synaptic protein SNAP-25 in cerebrospinal fluid in major depressive disorder and schizophrenia. |
| 260 | _ | _ | |a London |c 2025 |b BMJ Publ. Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1756977495_4384 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Decreased cerebrospinal fluid (CSF) levels of synaptic proteins, possibly reflecting impaired synaptic function, have been observed in major depressive disorder (MDD).To investigate the diagnostic utility of the soluble N-ethylmaleimide-sensitive-factor attachment receptor (SNARE) complex protein, synaptosomal-associated protein of 25 kDa (SNAP-25), for MDD.Overall, 208 participants with one of MDD, schizophrenia (SCZ) or bipolar disorder (BD), and healthy controls (HCs) were retrospectively enrolled. CSF levels of SNAP-25 were assessed relative to MDD characteristics and the diagnostic potential was analysed. In subgroups of patients, CSF levels of presynaptic neurexin 3 (NRXN3), postsynaptic neurogranin (NRGN) and Alzheimer's disease biomarkers were measured for comparison.SNAP-25 levels, but not the levels of the other synaptic markers, were significantly decreased in MDD compared with HCs, allowing for discrimination with 68% sensitivity and 67% specificity. SNAP-25 was not associated with MDD severity or antidepressant medication. Compared with HCs, SCZ also displayed decreased SNAP-25 enabling discrimination with 64% sensitivity and 77% specificity. There were strong correlations between levels of synaptic proteins and established Alzheimer pathology markers, with subtle differences in the association pattern between disorders.Our data suggest that SNAP-25, NRXN3 and NRGN versus beta-amyloid and phosphorylated tau protein 181 (ptau) are regulated differentially across psychiatric disorders and that SNAP-25 has a moderate diagnostic potential for MDD and SCZ. We propose that CSF SNAP-25 level might represent an integrated readout of reduced synaptic function, rather than of synaptic degeneration, in MDD. Further studies are needed to analyse whether this potential can be increased by using multimarker measurements and whether it will be possible to subtype psychiatric disorders according to synaptic involvement in pathophysiology.SNAP-25 and other synaptic proteins in CSF might aid diagnosis and subtyping of MDD and SCZ. The current development of sensitive methods to also determine synaptic proteins in blood samples from patients will advance the validation of the biomarker potential and contribute to understanding of synaptic involvement in the pathophysiology of MDD and SCZ. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Cross-Sectional Studies |2 Other |
| 650 | _ | 7 | |a Depression |2 Other |
| 650 | _ | 7 | |a Synaptosomal-Associated Protein 25 |2 NLM Chemicals |
| 650 | _ | 7 | |a Biomarkers |2 NLM Chemicals |
| 650 | _ | 7 | |a SNAP25 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Neurogranin |0 132654-77-4 |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Synaptosomal-Associated Protein 25: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Depressive Disorder, Major: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Depressive Disorder, Major: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Schizophrenia: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Schizophrenia: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Biomarkers: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Retrospective Studies |2 MeSH |
| 650 | _ | 2 | |a Neurogranin: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Bipolar Disorder: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Sensitivity and Specificity |2 MeSH |
| 700 | 1 | _ | |a Werner, Leonie |b 1 |
| 700 | 1 | _ | |a Tarabuko, Alexander |b 2 |
| 700 | 1 | _ | |a Al-Ali, Ilyas |b 3 |
| 700 | 1 | _ | |a Mechawar, Naguib |b 4 |
| 700 | 1 | _ | |a Pryce, Christopher R |b 5 |
| 700 | 1 | _ | |a Cattane, Nadia |b 6 |
| 700 | 1 | _ | |a Poggi, Giulia |b 7 |
| 700 | 1 | _ | |a Al Shweiki, Mhd Rami |b 8 |
| 700 | 1 | _ | |a Graf, Heiko |b 9 |
| 700 | 1 | _ | |a Großkopf, Henning |b 10 |
| 700 | 1 | _ | |a Halbgebauer, Steffen |0 P:(DE-2719)9002026 |b 11 |u dzne |
| 700 | 1 | _ | |a Oeckl, Patrick |0 P:(DE-2719)9001560 |b 12 |
| 700 | 1 | _ | |a Barba, Lorenzo |b 13 |
| 700 | 1 | _ | |a Meier, Laura |0 P:(DE-2719)9002179 |b 14 |u dzne |
| 700 | 1 | _ | |a Abu-Rumeileh, Samir |b 15 |
| 700 | 1 | _ | |a Marston, Hugh |b 16 |
| 700 | 1 | _ | |a Bornemann, Klaus D |b 17 |
| 700 | 1 | _ | |a Hengerer, Bastian |b 18 |
| 700 | 1 | _ | |a Danzer, Karin M |0 P:(DE-2719)9001513 |b 19 |u dzne |
| 700 | 1 | _ | |a Schönfeldt-Lecuona, Carlos |b 20 |
| 700 | 1 | _ | |a Otto, Markus |0 0000-0003-4273-4267 |b 21 |
| 773 | _ | _ | |a 10.1136/bmjment-2025-301752 |g Vol. 28, no. 1, p. e301752 - |0 PERI:(DE-600)3160283-6 |n 1 |p e301752 |t BMJ mental health |v 28 |y 2025 |x 1362-0347 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/280790/files/DZNE-2025-00974.pdf |y Restricted |
| 856 | 4 | _ | |u https://pub.dzne.de/record/280790/files/DZNE-2025-00974.pdf?subformat=pdfa |x pdfa |y Restricted |
| 909 | C | O | |o oai:pub.dzne.de:280790 |p VDB |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 11 |6 P:(DE-2719)9002026 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 12 |6 P:(DE-2719)9001560 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 14 |6 P:(DE-2719)9002179 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 19 |6 P:(DE-2719)9001513 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 1 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a National-Konsortium |0 StatID:(DE-HGF)0430 |2 StatID |d 2024-12-11 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-11 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2024-01-24T13:07:59Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2024-01-24T13:07:59Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2024-01-24T13:07:59Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-11 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-11 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2024-12-11 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2024-12-11 |
| 920 | 1 | _ | |0 I:(DE-2719)5000073 |k AG Öckl |l Translational Mass Spectrometry and Biomarker Research |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)5000072 |k AG Danzer |l Mechanisms of Propagation |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)5000073 |
| 980 | _ | _ | |a I:(DE-2719)5000072 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|